Literature DB >> 17608134

Effects of creating a non-specific, virus-hostile environment in the nasopharynx on symptoms and duration of common cold.

D Hull1, P Rennie, A Noronha, C Poore, N Harrington, V Fearnley, D Passàli.   

Abstract

The Common Cold remains the most frequent symptomatic viral infection in man. Current best therapies are all symptomatic. New pharmacological therapies are likely to be prescription-bound, and as most Common Cold infections are successfully treated without the intervention of a Physician, there is a need for effective non-prescription therapy options. Aim of this study is to propose a new type of approach, based on the concept of making a hostile biological environment for virus survival and spreading at the point of infection, the nasopharynx. The hypothesis was advanced that infections could be controlled using a physical biological approach to create an environment at the point of infection, that is inhibitory to the survival, and persistence of infecting virus, and of viruses newly released from infected mucosal epithelial cells. A nasal irrigation spray, designed to deliver a low pH gel to the nasal cavity, was developed and tested in this study. The study was a randomised, parallel, double-blind, placebo-controlled evaluation of three formulations of irrigation nasal spray in 441 subjects. The objective was to test whether the formulations reduced Cold severity and Cold duration compared to a placebo nasal spray. Subjects were recruited, and supplied with the product when healthy, and were instructed to begin treating and recording symptom severity once they experienced the "first signs" of a Common Cold. To qualify, subjects had to volunteer that they had at least one of the symptoms: sore/scratchy throat, runny nose or congested nose. The product was used 4 times daily, with at least 4 hours separating each dose, for a maximum of 7 days. Efficacy was assessed by an Interactive Voice Recall System whereby subjects were required to contact the investigation site, by telephone, twice daily when they were asked to assess the severity of their symptoms using a four point ordinal scale where 0 = "absent", and 3 = "severe". The symptoms assessed were sore throat, runny nose, blocked nose, cough and tired/run-down feeling. Two formulations demonstrated significant effects. A hydroxy methyl propyl cellulose based formulation reduced symptom severity compared with placebo by 17% and a Poloxamer based formulation reduced severity by 21%. Duration of illness was reduced with a hydroxy methyl propyl cellulose based formulation by 1.5 days to 2.4 days (according to the dose) and by a Poloxamer based formulation by 2.5 days. Results of this study suggest that the creation of a non virus-specific, inhibitory environment in the nasopharynx holds promise as an effective method of controlling the severity and duration of the Common Cold.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608134      PMCID: PMC2640010     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


  8 in total

1.  Productivity losses related to the common cold.

Authors:  Thomas J Bramley; Debra Lerner; Matthew Sames
Journal:  J Occup Environ Med       Date:  2002-09       Impact factor: 2.162

Review 2.  Antivirals for the common cold.

Authors:  T O Jefferson; D Tyrrell
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  PHLS primary care consultation--infectious disease and primary care research and service development priorities.

Authors:  C A McNulty; G E Smith; C Graham
Journal:  Commun Dis Public Health       Date:  2001-03

4.  Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial.

Authors:  R B Turner; M T Wecker; G Pohl; T J Witek; E McNally; R St George; B Winther; F G Hayden
Journal:  JAMA       Date:  1999-05-19       Impact factor: 56.272

Review 5.  Clinical significance and pathogenesis of viral respiratory infections.

Authors:  Jack M Gwaltney
Journal:  Am J Med       Date:  2002-04-22       Impact factor: 4.965

6.  The economic burden of non-influenza-related viral respiratory tract infection in the United States.

Authors:  A Mark Fendrick; Arnold S Monto; Brian Nightengale; Matthew Sarnes
Journal:  Arch Intern Med       Date:  2003-02-24

Review 7.  Pleconaril--an advance in the treatment of enteroviral infection in immuno-compromised patients.

Authors:  A D B Webster
Journal:  J Clin Virol       Date:  2005-01       Impact factor: 3.168

8.  The common cold: a review of the literature.

Authors:  Dennis Wat
Journal:  Eur J Intern Med       Date:  2004-04       Impact factor: 4.487

  8 in total
  5 in total

1.  Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.

Authors:  Mohammad Faheem Khan; Waseem Ahmad Ansari; Tanveer Ahamad; Mohsin Ali Khan; Zaw Ali Khan; Aqib Sarfraz; Mohd Aamish Khan
Journal:  J Mol Model       Date:  2022-07-06       Impact factor: 2.172

2.  Epipharyngeal Abrasive Therapy (EAT) Has Potential as a Novel Method for Long COVID Treatment.

Authors:  Kazuaki Imai; Takafumi Yamano; Soichiro Nishi; Ryushiro Nishi; Tatsuro Nishi; Hiroaki Tanaka; Toshiyuki Tsunoda; Shohei Yoshimoto; Ayaki Tanaka; Kenji Hiromatsu; Senji Shirasawa; Takashi Nakagawa; Kensuke Nishi
Journal:  Viruses       Date:  2022-04-27       Impact factor: 5.818

3.  Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey.

Authors:  Klang Shmuel; Megiddo Dalia; Lapidot Tair; Naparstek Yaakov
Journal:  Expert Rev Anti Infect Ther       Date:  2021-04-01       Impact factor: 5.091

Review 4.  Does Covera-19 know 'when to hold 'em or 'when to fold 'em? A translational thought experiment.

Authors:  Gerald Dieter Griffin
Journal:  Transl Med Commun       Date:  2021-06-30

Review 5.  Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.

Authors:  Vivek P Chavda; Lalitkumar K Vora; Anjali K Pandya; Vandana B Patravale
Journal:  Drug Discov Today       Date:  2021-07-29       Impact factor: 7.851

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.